{"component": "clause", "props": {"groups": [{"snippet_links": [{"key": "scheduled-meetings", "type": "clause", "offset": [55, 73]}, {"key": "written-summary", "type": "definition", "offset": [76, 91]}, {"key": "commercialization-activities", "type": "clause", "offset": [104, 132]}, {"key": "applicable-period", "type": "definition", "offset": [154, 171]}, {"key": "in-the-field", "type": "clause", "offset": [172, 184]}, {"key": "in-the-territory", "type": "clause", "offset": [185, 201]}, {"key": "commercialization-updates", "type": "clause", "offset": [204, 229]}], "samples": [{"hash": "cY0AWAWUjNB", "uri": "/contracts/cY0AWAWUjNB#commercial-updates", "label": "License, Development and Commercialization Agreement (Nanobiotix S.A.)", "score": 33.2655715942, "published": true}, {"hash": "qH40gYWW6A", "uri": "/contracts/qH40gYWW6A#commercial-updates", "label": "License, Development and Commercialization Agreement (Nanobiotix S.A.)", "score": 32.6851463318, "published": true}, {"hash": "2Dlhg6YAjRL", "uri": "/contracts/2Dlhg6YAjRL#commercial-updates", "label": "License, Development and Commercialization Agreement (LianBio)", "score": 32.4880218506, "published": true}], "snippet": "Lian shall provide to the JSC at each of its regularly-scheduled meetings a written summary of material Commercialization activities conducted during the applicable period in the Field in the Territory (\u201cCommercialization Updates\u201d).", "size": 4, "hash": "dcfb049e3f2d230d4060c2f4cb371849", "id": 1}, {"snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [0, 14]}, {"key": "commercialization-activities", "type": "clause", "offset": [61, 89]}, {"key": "with-respect-to", "type": "clause", "offset": [90, 105]}, {"key": "the-products", "type": "clause", "offset": [106, 118]}, {"key": "in-the-licensee-territory", "type": "clause", "offset": [119, 144]}, {"key": "agreed-by", "type": "definition", "offset": [188, 197]}, {"key": "such-information", "type": "definition", "offset": [396, 412]}, {"key": "level-of-detail", "type": "clause", "offset": [421, 436]}, {"key": "required-by", "type": "definition", "offset": [448, 459]}, {"key": "to-determine", "type": "definition", "offset": [469, 481]}, {"key": "compliance-with", "type": "clause", "offset": [493, 508]}, {"key": "diligence-obligations", "type": "clause", "offset": [513, 534]}, {"key": "sales-activities", "type": "definition", "offset": [610, 626]}, {"key": "marketing-activities", "type": "definition", "offset": [628, 648]}, {"key": "medical-affairs-activities", "type": "definition", "offset": [653, 679]}, {"key": "in-addition", "type": "clause", "offset": [681, 692]}, {"key": "corrective-plan", "type": "definition", "offset": [730, 745]}, {"key": "the-budget", "type": "definition", "offset": [800, 810]}, {"key": "cost-and-expense", "type": "clause", "offset": [822, 838]}, {"key": "current-year", "type": "clause", "offset": [899, 911]}, {"key": "previous-year", "type": "definition", "offset": [916, 929]}], "samples": [{"hash": "iTSRn3qM28d", "uri": "/contracts/iTSRn3qM28d#commercial-updates", "label": "Collaboration and License Agreement (Exelixis, Inc.)", "score": 35.1095140315, "published": true}, {"hash": "3rLpwxDFc5G", "uri": "/contracts/3rLpwxDFc5G#commercial-updates", "label": "Collaboration and License Agreement", "score": 30.3408622742, "published": true}, {"hash": "asaZmCPof37", "uri": "/contracts/asaZmCPof37#commercial-updates", "label": "Collaboration and License Agreement (Exelixis, Inc.)", "score": 27.7460651398, "published": true}], "snippet": "Licensee shall update the JCC on a [ * ] basis regarding its Commercialization activities with respect to the Products in the Licensee Territory. Each such update shall be in a form to be agreed by the JCC and shall summarize Licensee\u2019s, its Affiliates\u2019 and Sublicensees\u2019 significant Commercialization activities with respect to the Products in the Licensee Territory, and shall contain at least such information at such level of detail reasonably required by Exelixis to determine Licensee\u2019s compliance with its diligence obligations set forth herein. Such updates shall include, on a [ * ] basis, Licensee\u2019s sales activities, marketing activities and Medical Affairs Activities. In addition, if Licensee is then working under a corrective plan under Section 6.3(c), such updates shall also include the budget and actual cost and expense (including FTE levels) for such activities in [ * ] for the current year and previous year.", "size": 4, "hash": "5d28889dbeca109fc22ad409a7158fcd", "id": 2}, {"snippet_links": [{"key": "commercialization-activities", "type": "clause", "offset": [65, 93]}, {"key": "with-respect-to", "type": "clause", "offset": [94, 109]}, {"key": "the-products", "type": "clause", "offset": [110, 122]}, {"key": "collaborator-territory", "type": "definition", "offset": [130, 152]}, {"key": "agreed-by", "type": "definition", "offset": [196, 205]}, {"key": "such-information", "type": "definition", "offset": [413, 429]}, {"key": "level-of-detail", "type": "clause", "offset": [438, 453]}, {"key": "required-by", "type": "definition", "offset": [465, 476]}, {"key": "to-determine", "type": "definition", "offset": [486, 498]}, {"key": "compliance-with", "type": "clause", "offset": [514, 529]}, {"key": "diligence-obligations", "type": "clause", "offset": [534, 555]}, {"key": "sales-activities", "type": "definition", "offset": [616, 632]}, {"key": "marketing-activities", "type": "definition", "offset": [634, 654]}, {"key": "medical-affairs-activities", "type": "definition", "offset": [660, 686]}], "samples": [{"hash": "hiVT6Chi6wE", "uri": "/contracts/hiVT6Chi6wE#commercial-updates", "label": "Collaboration and License Agreement (Exelixis, Inc.)", "score": 33.3531837463, "published": true}, {"hash": "5HxKlf6kKTI", "uri": "/contracts/5HxKlf6kKTI#commercial-updates", "label": "Collaboration and License Agreement (Exelixis, Inc.)", "score": 28.5318279266, "published": true}, {"hash": "2hIwdR9CF0O", "uri": "/contracts/2hIwdR9CF0O#commercial-updates", "label": "Collaboration and License Agreement (Exelixis, Inc.)", "score": 28.3292274475, "published": true}], "snippet": "Collaborator shall update the JCC on a [ * ] basis regarding its Commercialization activities with respect to the Products in the Collaborator Territory. Each such update shall be in a form to be agreed by the JCC and shall summarize Collaborator\u2019s, its Affiliates\u2019, and Sublicensees\u2019 significant Commercialization activities with respect to the Products in the Collaborator Territory, and shall contain at least such information at such level of detail reasonably required by Exelixis to determine Collaborator\u2019s compliance with its diligence obligations set forth herein. Such updates shall include Collaborator\u2019s sales activities, marketing activities, and Medical Affairs Activities.", "size": 3, "hash": "ecd08bf59fcf03671372010176207f5f", "id": 3}, {"snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [0, 14]}, {"key": "commercialization-activities", "type": "clause", "offset": [59, 87]}, {"key": "with-respect-to", "type": "clause", "offset": [88, 103]}, {"key": "the-products", "type": "clause", "offset": [104, 116]}, {"key": "in-the-licensee-territory", "type": "clause", "offset": [117, 142]}, {"key": "agreed-by", "type": "definition", "offset": [186, 195]}, {"key": "such-information", "type": "definition", "offset": [397, 413]}, {"key": "level-of-detail", "type": "clause", "offset": [419, 434]}, {"key": "required-by", "type": "definition", "offset": [446, 457]}, {"key": "to-determine", "type": "definition", "offset": [463, 475]}, {"key": "compliance-with", "type": "clause", "offset": [487, 502]}, {"key": "diligence-obligations", "type": "clause", "offset": [507, 528]}, {"key": "section-63", "type": "clause", "offset": [547, 558]}, {"key": "sales-activities", "type": "definition", "offset": [598, 614]}, {"key": "sales-forecasts", "type": "definition", "offset": [616, 631]}, {"key": "marketing-activities", "type": "definition", "offset": [661, 681]}, {"key": "medical-affairs-activities", "type": "definition", "offset": [687, 713]}], "samples": [{"hash": "lWxaRbPCUI8", "uri": "/contracts/lWxaRbPCUI8#commercial-updates", "label": "Collaboration and License Agreement (Ovid Therapeutics Inc.)", "score": 32.2005462646, "published": true}, {"hash": "4nOZIQViw3v", "uri": "/contracts/4nOZIQViw3v#commercial-updates", "label": "Collaboration and License Agreement (Ovid Therapeutics Inc.)", "score": 31.8665294647, "published": true}], "snippet": "Licensee shall update the CGB on [***] basis regarding its Commercialization activities with respect to the Products in the Licensee Territory. Each such update shall be in a form to be agreed by the CGB and shall summarize Licensee\u2019s and its Affiliates\u2019 and Sublicensees\u2019 significant Commercialization activities with respect to the Products in the Licensee Territory, and shall contain at least such information at a level of detail reasonably required by Ovid to determine Licensee\u2019s compliance with its diligence obligations set forth in this Section 6.3. Such updates shall include Licensee\u2019s sales activities, sales forecasts for at least the next [***], marketing activities, and Medical Affairs Activities.", "size": 2, "hash": "0b08e94bf869b236d1586818bac804b0", "id": 4}, {"snippet_links": [{"key": "annual-basis", "type": "clause", "offset": [38, 50]}, {"key": "commercialization-activities", "type": "clause", "offset": [65, 93]}, {"key": "with-respect-to", "type": "clause", "offset": [94, 109]}, {"key": "licensed-products", "type": "definition", "offset": [114, 131]}, {"key": "in-english", "type": "definition", "offset": [187, 197]}, {"key": "agreed-by", "type": "definition", "offset": [218, 227]}, {"key": "such-information", "type": "definition", "offset": [442, 458]}, {"key": "level-of-detail", "type": "clause", "offset": [467, 482]}, {"key": "required-by", "type": "definition", "offset": [494, 505]}, {"key": "to-determine", "type": "definition", "offset": [515, 527]}, {"key": "compliance-with", "type": "clause", "offset": [541, 556]}, {"key": "diligence-obligations", "type": "clause", "offset": [561, 582]}, {"key": "section-63", "type": "clause", "offset": [601, 612]}, {"key": "sales-activities", "type": "definition", "offset": [654, 670]}, {"key": "sales-forecasts", "type": "definition", "offset": [672, 687]}, {"key": "marketing-activities", "type": "definition", "offset": [727, 747]}, {"key": "medical-affairs-activities", "type": "definition", "offset": [753, 779]}], "samples": [{"hash": "cxBdFpYgubp", "uri": "/contracts/cxBdFpYgubp#commercial-updates", "label": "Licensing Agreement", "score": 35.1718978882, "published": true}, {"hash": "9fFiXihSAai", "uri": "/contracts/9fFiXihSAai#commercial-updates", "label": "License and Collaboration Agreement (Gemphire Therapeutics Inc.)", "score": 30.5605754852, "published": true}], "snippet": "Beijing SL shall update the JSC on an annual basis regarding its Commercialization activities with respect to the Licensed Products in the Beijing SL Territory. Each such update shall be in English and in a form to be agreed by the JSC and shall summarize Beijing SL\u2019s and its Affiliates\u2019 and Sublicensees\u2019 significant Commercialization activities with respect to the Licensed Products in the Beijing SL Territory, and shall contain at least such information at such level of detail reasonably required by Gemphire to determine Beijing SL\u2019s compliance with its diligence obligations set forth in this Section 6.3. Such updates shall include Beijing SL\u2019s sales activities, sales forecasts for at least the next three (3) years, marketing activities, and Medical Affairs Activities.", "size": 2, "hash": "d4b7f211160c287cde67af8919ac8987", "id": 5}, {"snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [0, 14]}, {"key": "meetings-of", "type": "clause", "offset": [45, 56]}, {"key": "regulatory-developments", "type": "clause", "offset": [57, 80]}, {"key": "relating-to", "type": "definition", "offset": [81, 92]}, {"key": "the-products", "type": "clause", "offset": [93, 105]}, {"key": "in-the-licensee-territory", "type": "clause", "offset": [106, 131]}, {"key": "promptly-notify", "type": "definition", "offset": [142, 157]}, {"key": "in-writing", "type": "definition", "offset": [167, 177]}, {"key": "any-action", "type": "definition", "offset": [181, 191]}, {"key": "regulatory-authority", "type": "definition", "offset": [211, 231]}, {"key": "review-and-comment", "type": "clause", "offset": [317, 335]}, {"key": "regulatory-materials", "type": "clause", "offset": [346, 366]}, {"key": "as-soon-as-practicable", "type": "definition", "offset": [367, 389]}, {"key": "in-advance", "type": "clause", "offset": [390, 400]}, {"key": "date-of-submission", "type": "definition", "offset": [419, 437]}, {"key": "by-licensor", "type": "clause", "offset": [540, 551]}, {"key": "to-the-extent", "type": "clause", "offset": [553, 566]}], "samples": [{"hash": "aDBFKwaI5Bo", "uri": "/contracts/aDBFKwaI5Bo#commercial-updates", "label": "License Agreement (Jaguar Health, Inc.)", "score": 33.5475692749, "published": true}, {"hash": "bgyK2p0WSZS", "uri": "/contracts/bgyK2p0WSZS#commercial-updates", "label": "License Agreement (Jaguar Health, Inc.)", "score": 32.6440811157, "published": true}], "snippet": "Licensee shall keep Licensor informed at JSC meetings of regulatory developments relating to the Products in the Licensee Territory and shall promptly notify Licensor in writing of any action or decision by any Regulatory Authority in the Licensee Territory regarding the Product. Licensee shall provide Licensor for review and comment all draft Regulatory Materials as soon as practicable in advance of their intended date of submission to a Regulatory Authority in the Licensee Territory, and shall consider any comments thereto provided by Licensor, to the extent reasonable and practicable.", "size": 2, "hash": "4f669052edcc0d57174bac1cfdbf5175", "id": 6}, {"snippet_links": [{"key": "commercialization-activities", "type": "clause", "offset": [70, 98]}, {"key": "with-respect-to", "type": "clause", "offset": [99, 114]}, {"key": "licensed-products", "type": "definition", "offset": [115, 132]}, {"key": "a-credit", "type": "definition", "offset": [226, 234]}, {"key": "acceptance-fee", "type": "definition", "offset": [251, 265]}, {"key": "in-the-territory", "type": "clause", "offset": [266, 282]}, {"key": "level-of-detail", "type": "clause", "offset": [508, 523]}, {"key": "required-by", "type": "definition", "offset": [535, 546]}, {"key": "to-determine", "type": "definition", "offset": [557, 569]}, {"key": "diligence-obligations", "type": "clause", "offset": [597, 618]}, {"key": "provided-however", "type": "clause", "offset": [637, 653]}, {"key": "updates-and-reports", "type": "clause", "offset": [664, 683]}, {"key": "compliance-with-this-section", "type": "clause", "offset": [722, 750]}, {"key": "existing-reports", "type": "clause", "offset": [773, 789]}, {"key": "internal-communications", "type": "definition", "offset": [794, 817]}, {"key": "research-management-committee", "type": "clause", "offset": [825, 854]}, {"key": "executive-management", "type": "definition", "offset": [864, 884]}, {"key": "information-required", "type": "clause", "offset": [938, 958]}, {"key": "section-53", "type": "clause", "offset": [970, 981]}], "samples": [{"hash": "1ldg9ozEF5z", "uri": "/contracts/1ldg9ozEF5z#commercial-updates", "label": "Collaboration and License Agreement (Ionis Pharmaceuticals Inc)", "score": 32.8384666443, "published": true}], "snippet": "Ionis shall update BicycleTx on [***] basis regarding its significant Commercialization activities with respect to Licensed Products corresponding to each Target for which Ionis has paid (or, for [***], as applicable, applied a credit toward) the IND Acceptance Fee in the Territory. Each such update shall summarize Ionis and its Affiliates\u2019 and Sublicensees\u2019 significant Commercialization activities with respect to each such Licensed Product and Target in the Territory and shall contain information at a level of detail reasonably required by BicycleTx to determine Ionis\u2019 compliance with its diligence obligations set forth herein, provided however that such updates and reports need not be specifically generated in compliance with this section and Ionis may rely on existing reports and internal communications to its Research Management Committee or other executive management, as long as such reports appropriately encompass the information required under this Section 5.3.", "size": 1, "hash": "1d060b72b493e1b42c27b881cf14f13c", "id": 7}, {"snippet_links": [{"key": "written-reports", "type": "definition", "offset": [32, 47]}, {"key": "commercialization-activities", "type": "clause", "offset": [83, 111]}, {"key": "with-respect-to", "type": "clause", "offset": [112, 127]}, {"key": "licensed-products", "type": "definition", "offset": [128, 145]}, {"key": "in-the-territory", "type": "clause", "offset": [146, 162]}, {"key": "last-reporting-date", "type": "definition", "offset": [347, 366]}], "samples": [{"hash": "7AgAMqnYphw", "uri": "/contracts/7AgAMqnYphw#commercial-updates", "label": "Collaboration and License Agreement (Adagene Inc.)", "score": 33.3148536682, "published": true}], "snippet": "Sanofi shall provide to Adagene written reports on [***] regarding its significant Commercialization activities with respect to Licensed Products in the Territory. Each such written report shall summarize in reasonable detail Sanofi\u2019s, its Affiliates\u2019, and Sublicensees\u2019 significant Commercialization activities that have been conducted since the last reporting date and that are planned [***] with respect to the Commercialization of each Licensed Product in the Territory.", "size": 1, "hash": "67125acbdb40c10ead373e888815aa0f", "id": 8}, {"snippet_links": [{"key": "annual-basis", "type": "clause", "offset": [32, 44]}, {"key": "commercialization-activities", "type": "clause", "offset": [71, 99]}, {"key": "with-respect-to", "type": "clause", "offset": [100, 115]}, {"key": "in-the-territory", "type": "clause", "offset": [125, 141]}, {"key": "level-of-detail", "type": "clause", "offset": [346, 361]}, {"key": "required-by", "type": "definition", "offset": [373, 384]}, {"key": "to-determine", "type": "definition", "offset": [393, 405]}, {"key": "compliance-with", "type": "clause", "offset": [413, 428]}, {"key": "diligence-obligations", "type": "clause", "offset": [433, 454]}, {"key": "the-foregoing", "type": "definition", "offset": [484, 497]}, {"key": "updates-and-reports", "type": "clause", "offset": [524, 543]}, {"key": "the-requirements", "type": "clause", "offset": [613, 629]}, {"key": "section-63", "type": "clause", "offset": [638, 649]}, {"key": "existing-reports", "type": "clause", "offset": [693, 709]}, {"key": "internal-communications", "type": "definition", "offset": [714, 737]}, {"key": "executive-management", "type": "definition", "offset": [745, 765]}], "samples": [{"hash": "gvRxgWCy4da", "uri": "/contracts/gvRxgWCy4da#commercial-updates", "label": "License Agreement (VYNE Therapeutics Inc.)", "score": 32.8576316833, "published": true}], "snippet": "VYNE shall update In4Derm on an annual basis regarding its significant Commercialization activities with respect to Products in the Territory. Each such update shall summarize VYNE and its Affiliates\u2019 and Sublicensees\u2019 significant Commercialization activities with respect to each such Product in the Territory and shall contain information at a level of detail reasonably required by In4Derm to determine VYNE\u2019s compliance with its diligence obligations set forth herein. Subject to the foregoing, In4Derm agrees that such updates and reports need not be specifically generated and VYNE may satisfy 254821559 v1 the requirements of this Section 6.3 through updates which comprise appropriate existing reports and internal communications to its executive management.", "size": 1, "hash": "75d824a86ec72d34f1d1d1d165e16439", "id": 9}, {"snippet_links": [{"key": "licensee-shall", "type": "clause", "offset": [0, 14]}, {"key": "commercialization-activities", "type": "clause", "offset": [61, 89]}, {"key": "with-respect-to", "type": "clause", "offset": [90, 105]}, {"key": "the-products", "type": "clause", "offset": [106, 118]}, {"key": "in-the-licensee-territory", "type": "clause", "offset": [119, 144]}, {"key": "agreed-by", "type": "definition", "offset": [188, 197]}, {"key": "such-information", "type": "definition", "offset": [396, 412]}, {"key": "certain-confidential-information", "type": "clause", "offset": [438, 470]}, {"key": "contained-in", "type": "definition", "offset": [471, 483]}, {"key": "not-material", "type": "clause", "offset": [559, 571]}, {"key": "would-be-competitively-harmful-if-publicly-disclosed", "type": "clause", "offset": [581, 633]}, {"key": "required-by", "type": "definition", "offset": [653, 664]}, {"key": "to-determine", "type": "definition", "offset": [674, 686]}, {"key": "compliance-with", "type": "clause", "offset": [698, 713]}, {"key": "diligence-obligations", "type": "clause", "offset": [718, 739]}, {"key": "sales-activities", "type": "definition", "offset": [815, 831]}, {"key": "marketing-activities", "type": "definition", "offset": [833, 853]}, {"key": "medical-affairs-activities", "type": "definition", "offset": [858, 884]}, {"key": "in-addition", "type": "clause", "offset": [886, 897]}, {"key": "corrective-plan", "type": "definition", "offset": [935, 950]}, {"key": "the-budget", "type": "definition", "offset": [1005, 1015]}, {"key": "cost-and-expense", "type": "clause", "offset": [1027, 1043]}, {"key": "current-year", "type": "clause", "offset": [1104, 1116]}, {"key": "previous-year", "type": "definition", "offset": [1121, 1134]}], "samples": [{"hash": "jeb3qAA8Vnh", "uri": "/contracts/jeb3qAA8Vnh#commercial-updates", "label": "Collaboration and License Agreement (Exelixis, Inc.)", "score": 32.3429145813, "published": true}], "snippet": "Licensee shall update the JCC on a [ * ] basis regarding its Commercialization activities with respect to the Products in the Licensee Territory. Each such update shall be in a form to be agreed by the JCC and shall summarize Licensee\u2019s, its Affiliates\u2019 and Sublicensees\u2019 significant Commercialization activities with respect to the Products in the Licensee Territory, and shall contain at least such information at such level of [ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. detail reasonably required by Exelixis to determine Licensee\u2019s compliance with its diligence obligations set forth herein. Such updates shall include, on a [ * ] basis, Licensee\u2019s sales activities, marketing activities and Medical Affairs Activities. In addition, if Licensee is then working under a corrective plan under Section 6.3(c), such updates shall also include the budget and actual cost and expense (including FTE levels) for such activities in [ * ] for the current year and previous year.", "size": 1, "hash": "0af80b110b75ab3148cf1398990686c5", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2Ihtjb21tZXJjaWFsLXVwZGF0ZXMjMDAwMDAwMGEMogECZW4YACAA", "clause": {"title": "Commercial Updates", "size": 26, "children": [["commercialization-in-exelixis-territory", "Commercialization in Exelixis Territory"], ["pricing", "Pricing"], ["advisory-panels", "Advisory Panels"], ["sharing-of-promotional-materials", "Sharing of Promotional Materials"], ["generally", "Generally"]], "parents": [["commercialization", "Commercialization"], ["diligence", "Diligence"], ["commercialization-and-marketing", "Commercialization and Marketing"], ["commercialization-coordination", "Commercialization Coordination"], ["1general", "1General"]], "id": "commercial-updates", "related": [["commercial-use", "Commercial Use", "Commercial Use"], ["software-updates", "Software Updates", "Software Updates"], ["progress-update", "Progress Update", "Progress Update"], ["updates", "Updates", "Updates"], ["technical-evaluation", "TECHNICAL EVALUATION", "TECHNICAL EVALUATION"]], "related_snippets": [], "updated": "2026-02-12T04:24:58+00:00", "also_ask": [], "drafting_tip": null, "explanation": "The 'Commercial Updates' clause establishes the process by which parties communicate and implement changes to the commercial terms of their agreement. Typically, this clause outlines how updates regarding pricing, product offerings, or service terms are to be notified, often requiring written notice or mutual agreement before changes take effect. Its core function is to ensure both parties remain informed and in agreement about any modifications to the commercial aspects of their relationship, thereby reducing misunderstandings and disputes over evolving business terms."}, "json": true, "cursor": ""}}